ArticleMolecular and cellular biology2003
BRCA1 inhibition of telomerase activity in cultured cells.
Article in Molecular and cellular biology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 88 citations in OpenAlex.
- G-quadruplexes and associated proteins in aging and Alzheimer's disease.Frontiers in aging · 2023Review
- Article
- Review
- BRCA1 binds TERRA RNA and suppresses R-Loop-based telomeric DNA damage.Nature communications · 2021Article
- Assessment of telomerase as drug target in breast cancer.Journal of biosciences · 2020Review
- Effects of 3300 del A-1061 TerInternational journal of molecular epidemiology and genetics · 2019Article
- Functional role ofOncotarget · 2017Article
- Regulation of Telomere Homeostasis during Epstein-Barr virus Infection and Immortalization.Viruses · 2017Review
- Differential requirements for DNA repair proteins in immortalized cell lines using alternative lengthening of telomere mechanisms.Genes, chromosomes & cancer · 2017Article
- RNA-Seq based genome-wide analysis reveals loss of inter-chromosomal regulation in breast cancer.Scientific reports · 2017Article
- The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription.Oncotarget · 2016Article
- Review
- Strong preference of BRCA1 protein to topologically constrained non-B DNA structures.BMC molecular biology · 2016Article
- BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo.Oncotarget · 2016Article
- Article
- DNA and RNA quadruplex-binding proteins.International journal of molecular sciences · 2014Review
- Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Article
- Human ovarian tissue cortex surrounding benign and malignant lesions.Reproductive sciences (Thousand Oaks, Calif.) · 2014Article
- Article
- Telomerase as a useful target in cancer fighting-the breast cancer case.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Telomerase, an enzyme that maintains telomere length, plays major roles in cellular immortalization and cancer progression. We found that an exogenous BRCA1 gene strongly inhibited telomerase enzymatic activity in human prostate and breast cancer cell lines and caused telomere shortening in cell lines expressing wild-type BRCA1 (wtBRCA1) but not a tumor-associated mutant BRCA1 (T300G). wtBRCA1 inhibited the expression of the catalytic subunit (telomerase reverse transcriptase [TERT]) but had no effect on the expression of a subset of other components of the telomerase holoenzyme or on the expression of c-Myc, a transcriptional activator of TERT. However, endogenous BRCA1 associated and partially colocalized with c-Myc; exogenous wtBRCA1 strongly suppressed TERT promoter activity in various cell lines. The TERT inhibition was due, in part, to suppression of c-Myc E-box-mediated transcriptional activity. Suppression of TERT promoter and c-Myc activity required the amino terminus of BRCA1 but not the carboxyl terminus. Finally, endogenous BRCA1 and c-Myc were detected on transfected mouse and human TERT promoter segments in vivo. We postulate that inhibition of telomerase may contribute to the BRCA1 tumor suppressor activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.